Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 10 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Bellerophon Therapeutics, Inc. | 6,435,173 | reported | 28 Oct 2019 | tx 6+475,000−1,093,847 |
| KalVista Pharmaceuticals, Inc. | 5,117,285 | reported | 11 Feb 2025 | tx 10+422,092 |
| Cogent Biosciences, Inc. | 4,355,273 | reported | 18 Aug 2020 | tx 3+451,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 07 Feb 2025 | PURCHASE | KalVista Pharmaceuticals, Inc. | 73,649 | 9.29 USD | first after silence |
| 11 Feb 2025 | PURCHASE | KalVista Pharmaceuticals, Inc. | 26,703 | 9.18 USD | |
| 10 Feb 2025 | PURCHASE | KalVista Pharmaceuticals, Inc. | 4,137 | 9.14 USD | |
| 30 Jan 2024 | PURCHASE | KalVista Pharmaceuticals, Inc. | 88,099 | 14.47 USD | |
| 26 Jan 2024 | PURCHASE | KalVista Pharmaceuticals, Inc. | 4,174 | 12.98 USD | |
| 25 Jan 2024 | PURCHASE | KalVista Pharmaceuticals, Inc. | 7,030 | 12.73 USD | |
| 29 Jan 2024 | PURCHASE | KalVista Pharmaceuticals, Inc. | 80,600 | 14.22 USD | |
| 08 Jan 2024 | PURCHASE | KalVista Pharmaceuticals, Inc. | 69,184 | 12.44 USD | first after silence |
| 10 Jan 2024 | PURCHASE | KalVista Pharmaceuticals, Inc. | 47,700 | 12.67 USD | |
| 09 Jan 2024 | PURCHASE | KalVista Pharmaceuticals, Inc. | 20,816 | 12.56 USD | |
| 17 Aug 2020 | PURCHASE | Cogent Biosciences, Inc. | 250,000 | 2.57 USD | |
| 18 Aug 2020 | PURCHASE | Cogent Biosciences, Inc. | 101,000 | 2.62 USD | |
| 14 Aug 2020 | PURCHASE | Cogent Biosciences, Inc. | 100,000 | 2.30 USD | first after silence |
| 28 Oct 2019 | SALE | Bellerophon Therapeutics, Inc. | 333,010 | 0.44 USD | |
| 24 Oct 2019 | SALE | Bellerophon Therapeutics, Inc. | 704,595 | 0.50 USD | |
| 25 Oct 2019 | SALE | Bellerophon Therapeutics, Inc. | 56,242 | 0.45 USD | |
| 10 Sept 2018 | PURCHASE | Bellerophon Therapeutics, Inc. | 200,000 | 1.22 USD | |
| 12 Sept 2018 | PURCHASE | Bellerophon Therapeutics, Inc. | 75,000 | 1.15 USD | |
| 11 Sept 2018 | PURCHASE | Bellerophon Therapeutics, Inc. | 200,000 | 1.14 USD |
3 purchases reported after at least 12 months of silence — most recent on 07 Feb 2025.